Want to see XCUR full AI Analyst Report?
XCUR Stock Chart & Stats
$5.93
-$0.13(-1.36%)
At close: 4:00 PM EST
$5.93
-$0.13(-1.36%)
Day’s Range― - ―
52-Week Range$1.71 - $9.50
Previous CloseN/A
Volume39.94K
Average Volume (3M)23.77K
Market Cap
$12.17M
Enterprise Value$11.12M
Total Cash (Recent Filing)$2.60M
Total Debt (Recent Filing)$22.00K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding6,373,937
10 Day Avg. Volume33,737
30 Day Avg. Volume23,774
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-42.29
Enterprise Value/Ebitda-1.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary SNA PlatformOwnership of a differentiated SNA platform provides a durable technological moat for nucleic-acid therapeutics. A sustained platform advantage can enable multiple programs, licensing or partnerships, and long-term optionality across oncology and immunology even if near-term clinical readouts are delayed.
Governance And Leadership RefreshStrengthened governance and experienced operational hires reduce execution and oversight risk over the medium term. Formalized audit and compensation committees and settled derivative claims lower legal overhang and improve investor confidence in management processes and controls.
Materially Reduced LeverageElimination of balance-sheet debt materially lowers bankruptcy and financing risk, improving optionality for strategic choices. With no debt service, management can prioritize R&D, partnerships, or restructuring without near-term interest obligations that would otherwise exacerbate cash burn.
Bears Say
Pre-revenue With Ongoing Cash BurnBeing effectively pre-revenue while burning roughly $8M–$9M annually creates a durable funding requirement and execution risk. Continued negative operating and free cash flow limits internal reinvestment capacity and forces reliance on external financing or dilutive transactions to sustain operations.
Shrinking Equity CushionRapid erosion of shareholders' equity tightens the firm’s capital buffer against adverse outcomes. With a small equity base and ongoing losses, the company has less capacity to absorb setbacks, increasing the likelihood of dilutive financings or constrained strategic options over the medium term.
Pipeline Disruption And Strategic PivotStopping earlier clinical programs and pivoting strategy creates uncertainty about future value drivers and delays potential revenue paths. Pipeline discontinuity reduces near-term upside from clinical milestones and necessitates proving new program biology and commercial potential over additional, multi-quarter development cycles.
Exicure News
XCUR FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was $1.71 and its highest was $9.50 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is $12.17M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is Aug 07, 2026 which is in 34 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on May 13, 2026. The company reported -$0.287 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.287.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,373,937 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -$0.287 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.086%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in XCUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Technical Analysis
Ownership Overview
25.09% Insiders
0.94% Mutual Funds
0.88% Other Institutional Investors
72.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---